Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NPWQC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NY920-DAPA-VC-MMAE
|
|||||
| Synonyms |
NY920-DAPA-VC-MMAE
Click to Show/Hide
|
|||||
| Organization |
Novartis
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
NY920-DAPA
|
Antibody Info | ||||
| Antigen Name |
CD48 antigen (CD48)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Cysteine-maleimide conjugation
|
|||||
| Combination Type |
Vc-MMAE
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.026 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin
mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.
Click to Show/Hide
|
||||
| In Vitro Model | Multiple myeloma | KMS-21 cells | CVCL_2991 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.027 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin
mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.028 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin
mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.077 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin
mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-20 cells | CVCL_2990 | ||